The U.S. Court of Appeals for the Federal Circuit (CAFC) ruled in a precedential decision authored by Judge Prost on Monday that certain claims of Janssen Pharmaceuticals Inc.’s patent for a schizophrenia drug are not indefinite but vacated and remanded the district court’s finding that Teva Pharmaceuticals had not proven all of the claims obvious.
Recent Posts
- Pro Se Applicant Gets USPTO’s 101 Rejection Vacated at CAFC
- Split Third Circuit Upholds Medicare Price Negotiation Program Under Biden IRA
- U.S. Chamber-Led Coalition Joins Voices Telling Commerce to Nix Valuation-Based Patent Fee Proposal
- Trump Order Bars USPTO Patents Employees from POPA Membership But Will Not Yet Affect Telework
- CAFC Upholds Prosecution Laches Ruling Against Gil Hyatt